The global epigenetics drugs & diagnostic technologies market size is estimated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing geriatric population and increasing prevalence of cancer and chronic diseases.
Epigenetics is the study of heritable changes in gene expression (active vs inactive genes) that do not entail changes to the underlying DNA sequence — a phenotype without a genotype — which impacts how cells interpret genes. Epigenetic change is a common and normal process, although it may be impacted by a variety of factors such as age, lifestyle/environment, and disease state. Epigenetic changes are just as prevalent as the way cells ultimately differentiate to become skin cells, liver cells, brain cells, and so on. However, epigenetic changes can have more harmful consequences, such as the development of diseases such as cancer. At least three mechanisms are presently considered to initiate and maintain epigenetic change, which includes DNA methylation, histone modification, and non-coding RNA (ncRNA)-associated gene silencing. Errors in the epigenetic process can result in abnormal gene activity or inactivity, such as modifying the wrong gene or failing to add a chemical group to a specific gene or histone. Genetic diseases are frequently caused by altered gene activity, including that induced by epigenetic errors. Epigenetic errors have been linked to diseases including cancer, metabolic problems, and degenerative illnesses.
Epigenetics, an exciting and rapidly evolving field of medicine, is expanding medicine's potential well beyond the genome, delivering a new generation of diagnostic and therapeutic discoveries that provide hope to many patients suffering from life-threatening disorders. Epigenetic modifications are stable and produce strong signals as disease biomarkers, which may be mapped and quantified utilizing platforms like HMCP (5-hydroxymethylcytosine pull-down). Epigenetic biomarkers are disease-specific and tissue-specific biomarkers. Epigenetic modifications have been discovered to occur before genetic modifications, potentially allowing for illness diagnosis at an early stage. Clinical intervention will be possible with epigenetic-based diagnostics before symptom development has damaged quality of life, when patients are still reasonably fit and treatment success is more likely. Indeed, continual epigenome monitoring might become an essential disease prevention tool in the future, allowing for a more efficient and effective healthcare system. For many years, medicines and therapies that impact or disrupt epigenetic processes have been used, notably in the field of cancer (e.g., hypomethylating agents). The most recent generation of epigenetic medicines provides tailored therapy choices with the promise of fewer side effects. Epigenetic technology may also improve prognostic prediction and patient classification. Appropriate treatments can be chosen based on epigenetic state, resulting in improved treatment results and more accurate disease progression assessment.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing geriatric population and growing oncology and non-oncology diseases around the world are projected to boost the market growth during the forecast period.
- Increasing prevalence of cancer around the world with technological advancements in diagnostic techniques are anticipated to drive the market growth in the coming years.
- Increased consumer awareness regarding cancer symptoms, risk factors, early detection, and early treatment is expected to fuel the market growth during the forecast period.
- Longer R&D cycles for generating epigenetic medicines and lack of evidence of epigenetic therapy's efficacy in solid tumors are estimated to hamper the market growth during the forecast period.
- Increased R&D investments catering the increasing need for understanding epigenetic modifications at the molecular level and development of therapeutic solutions are expected to offer lucrative opportunities for the market players.
Scope of the Report
The report on the global epigenetics drugs & diagnostic technologies market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Epigenetics Drugs & Diagnostic Technologies Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Product (Reagents [Antibodies, PCR Reagents, Histones, Primers, Electrophoresis Reagents, Nucleic Acid Analysis Reagents, Buffers, And Others], Kits [ChIP Sequencing Kit, Whole Genomic Amplification Kit, Bisulfite Conversion Kit, RNA Sequencing Kit, and Others], Instruments, Enzymes, and Services), Technology (DNA Methylation, Histone Methylation, Histone Acetylation, Large Non-coding RNA, MicroRNA Modification, and Chromatin Structures), Type of Therapy (Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors), Application (Oncology [Solid Tumors and Liquid Tumors], Non-oncology [Inflammatory Diseases, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases, and Others])
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Roche Diagnostics; Thermo Fisher Scientific, Inc.; Eisai Co. Ltd.; Novartis AG; Illumina, Inc.; Merck Sharp & Dohme Corp; Qiagen; Abcam PLC; and Merck KGaA
|
Market Segment Insights
Kits segment is expected to account for a key share
Based on product, the epigenetics drugs & diagnostic technologies market is segmented into reagents, kits, instruments, enzymes, and services. The reagents segment is further sub segmented into antibodies, PCR reagents, histones, primers, electrophoresis reagents, nucleic acid analysis reagents, buffers, and others. The kits segment is further sub segmented into ChIP sequencing kit, whole genomic amplification kit, bisulfite conversion kit, RNA sequencing kit, and others. The kits segment is expected to account for a key share of the market during the forecast period owing to ready-to-use kits. Kits for nucleic acid purification, DNA methylation status analysis, and detection of histone modifications by different enzymes are all available on the market, as are kits for chromatin immunoprecipitation. Epigenetic diagnostic kits are used to diagnose diseases caused by epigenetic changes in the early phases of treatment and to monitor therapy efficacy. They work by using modification-specific monoclonal antibodies to carry out immunoprecipitation.
Histone acetylation segment is expected to account for constitute a key share
Based on technology, the epigenetics drugs & diagnostic technologies market is segmented into DNA methylation, histone methylation, histone acetylation, large non-coding RNA, microRNA modification, and chromatin structures. The histone acetylation segment is expected to account for constitute a key share of the market during the forecast period owing to enhanced efficacy due to the introduction of novel mechanisms. Histone acetylation is the addition of an acetyl group to lysine residues by an enzyme. Histone acetylation is involved in gene silencing, chromatin transcription and dynamics, cell cycle progression, differentiation, death, DNA replication, neural repression, nuclear import, and DNA repair, among other biological activities. Histone Acetyl Transferases (HATs) are involved in histone acetylation, whereas Histone Deacetylases are involved in histone deacetylation (HDACs).
On the other hand, the DNA methylation segment is anticipated to expand at a rapid pace during the forecast period owing to technological advancements which are enabling the assessment of locus-specific DNA methylation on genome-wide scale.
DNA methyltransferase segment is expected to constitute a key share
Based on type of therapy, the epigenetics drugs & diagnostic technologies market is bifurcated histone deacetylase (HDAC) inhibitors and DNA methyltransferase (DNMT) inhibitors. The DNA methyltransferase segment is expected to constitute a key share of the market during the forecast period owing to increased availability. Furthermore, this therapeutic class has a large number of generics available, which is expected to boost market growth.
On the other hand, the histone deacetylase inhibitors segment is anticipated to expand at a rapid pace during the forecast period owing to strong product pipeline and the commercial availability of a large number of medicines.
Oncology segment is expected to represent a key share
Based on application, the epigenetics drugs & diagnostic technologies market is bifurcated into oncology and non-oncology. The oncology segment is further sub segmented into solid tumors and liquid tumors. The non-oncology segment is further sub segmented into inflammatory diseases, metabolic diseases, infectious diseases, cardiovascular diseases, and others. The oncology segment is expected to represent a key share of the market during the forecast period due to increasing prevalence of cancer and increased number of deaths by cancer. Furthermore, the launch of new products and the possible future commercialization of products currently in the pipeline are expected to drive the segment growth.
On the other hand, the non-oncology segment is anticipated to expand at a rapid pace during the forecast period due to extensive research activities for the identification of epigenetic markers related to these disorders. Metabolic, neurodegenerative, and viral illnesses, as well as many other non-oncology conditions, have been linked to epigenetic changes. Furthermore, private institutions and biopharmaceutical firms are performing extensive research to identify biomarkers for drug development.
North America is anticipated to dominate
On the basis of regions, the epigenetics drugs & diagnostic technologies market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to government financing programs for current research activities, improved healthcare facilities, and increasing geriatric population. Furthermore, research efforts for a wide variety of cancer and non-oncology diseases, such as metabolic, inflammatory, cardiovascular, and other illnesses, are anticipated to be boosted by Common Fund-supported initiatives in the United States.
On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to increased disposable income, increasing unmet clinical needs, expanding awareness of early diagnosis, and availability of efficient treatment in emerging countries such as India and China. One of the major reasons for the rise in oncology and chronic disease patients is the growing geriatric population. This is likely to enhance the regional market growth even further. In this region, R&D activities involving the study of epigenetic base in various diseases are on the rise. The EpiGen Research Consortium, based in the United Kingdom, has expanded its research facility in Singapore to study chronic illnesses including diabetes and obesity.
Segments
Segments Covered in the Report
The global epigenetics drugs & diagnostic technologies market has been segmented on the basis of
Product
- Reagents
- Antibodies
- PCR reagents
- Histones
- Primers
- electrophoresis reagents
- nucleic acid analysis reagents
- buffers
- others
- Kits
- ChIP Sequencing Kit
- Whole Genomic Amplification Kit
- Bisulfite Conversion Kit
- RNA Sequencing Kit
- Others
- Instruments
- Enzymes
- Services
Technology
- Histone Methylation
- Histone Acetylation
- Large Non-coding RNA
- MicroRNA Modification
- Chromatin Structures
Type of Therapy
- Histone Deacetylase (HDAC) Inhibitors
- DNA Methyltransferase (DNMT) Inhibitors
Application
- Oncology
- Solid Tumors
- Liquid Tumors
- Non-oncology
- Inflammatory Diseases
- Metabolic Diseases
- Infectious Diseases
- Cardiovascular Diseases
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Roche Diagnostics
- Thermo Fisher Scientific, Inc.
- Eisai Co. Ltd.
- Novartis AG
- Illumina, Inc.
- Merck Sharp & Dohme Corp
- Qiagen
- Abcam PLC
- Merck KGaA
Competitive Landscape
Key players competing in the epigenetics drugs & diagnostic technologies market are Roche Diagnostics; Thermo Fisher Scientific, Inc.; Eisai Co. Ltd.; Novartis AG; Illumina, Inc.; Merck Sharp & Dohme Corp; Qiagen; Abcam PLC; and Merck KGaA.
Some of the key business strategies employed by companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.
Request For Customization
Enquiry Before Buying
Speak With Analyst
